Device Trial Radar · NCT06666699
RIVOS Feasibility (MBO)
Last checked: Nov 20, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Aug 31, 2025
Primary completion
May 30, 2026
Study completion May 30, 2026
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Oct 31, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess basic feasibility, safety, and performance of an EUS access device in patients with malignant biliary obstruction who are indicated to receive EUS-guided hepaticogastrostomy for biliary drainage. The main questions it aims to answer are: * Can the device be used to gain and maintain access to target anatomy? * Does the device have a clinically acceptable safety profile? * How does the device perform overall? All patients will undergo a hepaticogastrostomy procedure and be followed for 7 days post-procedure.
Conditions
- Malignant Biliary Obstruction
Interventions
EUS access deviceDevice
The intervention involves the use of an EUS access device to gain access to the bile duct via hepaticogastrostomy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Technical SuccessTime frame: Day 0 Study Procedure
2 more outcomes with a free account
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Ghent University Hospital
Ghent, Belgium
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.